Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 16.1% in the morning session after the company reported ...

The global pharmacogenomics market size is forecasted to reach approximately USD 43.09 billion by 2034 increasing from USD 17.92 billion in 2024, with a solid CAGR of 9.17% from 2025 to 2034. In terms ...

Myriad Genetics, Inc. MYGN reported fourth-quarter 2024 adjusted earnings of 3 cents per share, which came in line with the ...

Q4 2024 Earnings Call Transcript February 24, 2025 Operator: Good day, and thank you for standing by. Welcome to the Myriad ...

U.S. Pharmacogenomics Market Growth 2025 Pharmacogenomics, also known as pharmacogenetics, is a branch of genomic medicine that uses a pati ...

Hence, it is essential that IVDR allows for this flexibility. For example, the Clinical Pharmacogenomics Implementation Consortium (CPIC) guidelines 1 were last updated in January 2024 ...

Pharmacogenomics – an individual's genetic response to medications – is an increasingly important strand of personalised healthcare but little is known about the public's views on it.

How a person responds to medication is sometimes influenced by their genetic makeup. Some medications do not work as well for ...

Myriad Genetics Inc (MYGN) reports an 11% revenue increase and unveils a promising partnership with PATHOMIQ to enhance its ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

These results serve as an example of how population-centered approaches to pharmacogenomics can help to realize the promise of precision medicine in resource-limited settings. Colombia’s first ...